One year after the November 2015 FDA approval of mepolizumab (Nucala, GlaxoSmithKline) to treat severe asthma with eosinophilic phenotype, a review considers how initial studies missed its effectiveness, the subsequent evidence that supported its utility, and possible future applications.
Unlike other conditions, pulmonary hypertension has symptoms that can be hard to identify in order to give the patients the right diagnosis. Misdiagnosis can not only worsen the symptoms, but also make treatment that much harder in the long run.
For cardiologists, treating a patient with hypertension is becoming a more common and less complicated effort. However, a similar condition, called pulmonary hypertension, is not nearly as well understood, managed, or treated.
In many hospitals there is a consistent effort to monitor how patients are responding to various treatments. This can be done at different increments which can determine in some cases how effective treatments are against pathogens which can affect a patients' health.